These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 37984601)

  • 21. The association between the environmental endocrine disruptor bisphenol A and polycystic ovary syndrome: a systematic review and meta-analysis.
    Hu Y; Wen S; Yuan D; Peng L; Zeng R; Yang Z; Liu Q; Xu L; Kang D
    Gynecol Endocrinol; 2018 May; 34(5):370-377. PubMed ID: 29191127
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum lipoprotein lipid profile in women with the polycystic ovary syndrome: relation to anthropometric, endocrine and metabolic variables.
    Holte J; Bergh T; Berne C; Lithell H
    Clin Endocrinol (Oxf); 1994 Oct; 41(4):463-71. PubMed ID: 7955457
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Apolipoprotein B/A1 Ratio is Associated With Metabolic Syndrome Components, Insulin Resistance, Androgen Hormones, and Liver Enzymes in Women With Polycystic Ovary Syndrome.
    He H; Feng J; Zhang S; Wang Y; Li J; Gao J; Cong J; Gong Y; Wu X
    Front Endocrinol (Lausanne); 2021; 12():773781. PubMed ID: 35069437
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Connecting Bisphenol A Exposure to PCOS: Findings from a Case-Control Investigation.
    Patel J; Chaudhary H; Panchal S; Parekh B; Joshi R
    Reprod Sci; 2024 Aug; 31(8):2273-2281. PubMed ID: 38637475
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Role of 11-Oxygenated Androgens and Endocrine Disruptors in Androgen Excess Disorders in Women.
    Vitku J; Varausova A; Skodova T; Kolatorova L; Vosatkova M; Vcelak J; Vrbikova J; Simkova M; Svojtkova M
    Int J Mol Sci; 2024 Sep; 25(17):. PubMed ID: 39273637
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phenotype and metabolic profile of South Asian women with polycystic ovary syndrome (PCOS): results of a large database from a specialist Endocrine Clinic.
    Wijeyaratne CN; Seneviratne Rde A; Dahanayake S; Kumarapeli V; Palipane E; Kuruppu N; Yapa C; Seneviratne Rde A; Balen AH
    Hum Reprod; 2011 Jan; 26(1):202-13. PubMed ID: 21098627
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bisphenol A (BPA) and its potential role in the pathogenesis of the polycystic ovary syndrome (PCOS).
    Rutkowska A; Rachoń D
    Gynecol Endocrinol; 2014 Apr; 30(4):260-5. PubMed ID: 24397396
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Association Between Bisphenol A and Polycystic Ovarian Syndrome: A Case-Control Study.
    Hossein Rashidi B; Amanlou M; Behrouzi Lak T; Ghazizadeh M; Haghollahi F; Bagheri M; Eslami B
    Acta Med Iran; 2017 Dec; 55(12):759-764. PubMed ID: 29373882
    [TBL] [Abstract][Full Text] [Related]  

  • 29. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME - PART 2.
    Goodman NF; Cobin RH; Futterweit W; Glueck JS; Legro RS; Carmina E; ; ;
    Endocr Pract; 2015 Dec; 21(12):1415-26. PubMed ID: 26642102
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Soy but not bisphenol A (BPA) induces hallmarks of polycystic ovary syndrome (PCOS) and related metabolic co-morbidities in rats.
    Patisaul HB; Mabrey N; Adewale HB; Sullivan AW
    Reprod Toxicol; 2014 Nov; 49():209-18. PubMed ID: 25242113
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A mutispectroscopic study on the structure-affinity relationship of the interactions of bisphenol analogues with bovine serum albumin.
    Gu J; Huang X; Liu H; Dong D; Sun X
    Chemosphere; 2022 Mar; 291(Pt 1):132769. PubMed ID: 34740696
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BPA, BADGE and analogues: A new multi-analyte LC-ESI-MS/MS method for their determination and their in vitro (anti)estrogenic and (anti)androgenic properties.
    van Leeuwen SP; Bovee TF; Awchi M; Klijnstra MD; Hamers AR; Hoogenboom RL; Portier L; Gerssen A
    Chemosphere; 2019 Apr; 221():246-253. PubMed ID: 30640007
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In silico binding of 4,4'-bisphenols predicts in vitro estrogenic and antiandrogenic activity.
    Conroy-Ben O; Garcia I; Teske SS
    Environ Toxicol; 2018 May; 33(5):569-578. PubMed ID: 29392883
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Prevalence of Polycystic Ovary Syndrome, Its Phenotypes and Cardio-Metabolic Features in a Community Sample of Iranian Population: Tehran Lipid and Glucose Study.
    Farhadi-Azar M; Behboudi-Gandevani S; Rahmati M; Mahboobifard F; Khalili Pouya E; Ramezani Tehrani F; Azizi F
    Front Endocrinol (Lausanne); 2022; 13():825528. PubMed ID: 35299965
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolic syndrome and the risk of cardiovascular complications in young patients with different phenotypes of polycystic ovary syndrome.
    Krentowska A; Łebkowska A; Jacewicz-Święcka M; Hryniewicka J; Leśniewska M; Adamska A; Kowalska I
    Endocrine; 2021 May; 72(2):400-410. PubMed ID: 33442790
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Apa-I polymorphism in VDR gene is related to metabolic syndrome in polycystic ovary syndrome: a cross-sectional study.
    Santos BR; Lecke SB; Spritzer PM
    Reprod Biol Endocrinol; 2018 Apr; 16(1):38. PubMed ID: 29669566
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence of metabolic syndrome in women with polycystic ovary syndrome and the factors associated: A cross sectional study at a tertiary care center in Hyderabad, south-eastern India.
    Karee M; Gundabattula SR; Sashi L; Boorugu H; Chowdhury A
    Diabetes Metab Syndr; 2020; 14(4):583-587. PubMed ID: 32416528
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum zonulin level is not elevated in patients with polycystic ovary syndrome without metabolic syndrome.
    Cetin Z; Kosem A; Can B; Baser O; Catak M; Turhan T; Berker D
    Arch Gynecol Obstet; 2019 Dec; 300(6):1785-1790. PubMed ID: 31667610
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endocrine disruptors and polycystic ovary syndrome: a focus on Bisphenol A and its potential pathophysiological aspects.
    Palioura E; Kandaraki E; Diamanti-Kandarakis E
    Horm Mol Biol Clin Investig; 2014 Mar; 17(3):137-44. PubMed ID: 25372737
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bisphenol a downregulates GLUT4 expression by activating aryl hydrocarbon receptor to exacerbate polycystic ovary syndrome.
    Shi J; Hu KL; Li XX; Ge YM; Yu XJ; Zhao J
    Cell Commun Signal; 2024 Jan; 22(1):28. PubMed ID: 38200540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.